Cargando…

Use of anakinra in severe COVID-19: A case report

Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filocamo, Giovanni, Mangioni, Davide, Tagliabue, Paola, Aliberti, Stefano, Costantino, Giorgio, Minoia, Francesca, Bandera, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211644/ https://www.ncbi.nlm.nih.gov/pubmed/32437934 http://dx.doi.org/10.1016/j.ijid.2020.05.026

Ejemplares similares

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
por: Bozzi, Giorgio, et al.
Publicado: (2021)

Anakinra for severe forms of COVID-19
por: Laine, Marc, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19
por: Khan, Naim Akhtar
Publicado: (2020)

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
por: Pontali, Emanuele, et al.
Publicado: (2020)

COVID-19 multidisciplinary high dependency unit: the Milan model
por: Aliberti, Stefano, et al.
Publicado: (2020)

Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes
por: Lombardi, Andrea, et al.
Publicado: (2020)

Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy
por: Torre, Alessandro, et al.
Publicado: (2020)

Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
por: Kyriazopoulou, Evdoxia, et al.
Publicado: (2021)

Stigma at the time of the COVID-19 pandemic
por: Villa, Simone, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19 – Authors' reply
por: Hayem, Gilles, et al.
Publicado: (2020)

Anakinra: Jaundice: case report
Publicado: (2021)

Anakinra for patients with COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Maoujoud, Omar, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Valette, Xavier, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Martin-Silva, Nicolas, et al.
Publicado: (2020)

Effect of anakinra in COVID-19
por: Kooistra, Emma J, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19: a cohort study
por: Huet, Thomas, et al.
Publicado: (2020)

Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results
por: Lombardi, Andrea, et al.
Publicado: (2021)

A case of classic neuromyelitis optica (Devic’s syndrome) triggered by pegylated-interferon α
por: Mangioni, Davide, et al.
Publicado: (2014)

Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia
por: Pontali, Emanuele, et al.
Publicado: (2021)

Anakinra/steroids: Cytomegalovirus viremia: case report
Publicado: (2022)

High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report
por: Shafferman, Ashley, et al.
Publicado: (2014)

Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment
por: Bertoni, Arinna, et al.
Publicado: (2022)

Schnitzler Syndrome: A Dramatic Response to Anakinra
por: Gouveia, Ana Isabel, et al.
Publicado: (2016)

Can early-onset acquired demyelinating syndrome (ADS) hide pediatric Behcet's disease? A case report
por: Pozzato, Mattia, et al.
Publicado: (2023)

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
por: Dimopoulos, George, et al.
Publicado: (2020)

Juvenile idiopathic arthritis in Harlequin ichthyosis, a rare combination or the clinical spectrum of the disease? Report of a child treated with etanercept and review of the literature
por: Baldo, Francesco, et al.
Publicado: (2021)

Anakinra/tocilizumab: Primary biliary cholangitis: case report
Publicado: (2021)

Methylprednisolone/infliximab/anakinra: Lack of efficacy: case report
Publicado: (2021)

Anakinra: Drug-induced liver injury: case report
Publicado: (2021)

Anakinra/dexamethasone/etoposide: Lack of efficacy: case report
Publicado: (2021)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

Anakinra: a silver lining in COVID-19?
por: Gupta, Rahul
Publicado: (2020)

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Current evidence on the use of anakinra in COVID-19
por: Khani, Elnaz, et al.
Publicado: (2022)

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
por: Franzetti, Marco, et al.
Publicado: (2020)

Adalimumab/anakinra/dexamethasone: COVID-19 infection, cytomegalovirus reactivation and off-label use: case report
Publicado: (2020)

Focal bone lesions in hiv-positive patient treated with tenofovir
por: Mangioni, Davide, et al.
Publicado: (2014)

Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report
por: Karadeniz, Hazan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tqg4gfv9gsl8sib231j15ancal